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ABSTRACT: Hepatitis B virus core (HBc) particles acquire
the capacity to disassemble and reassemble in a controlled
manner, allowing entrapment and delivery of drugs and
macromolecules to cells. HBc particles are made of 180−240
copies of 21 kDa protein monomers, assembled into 30−34
nm diameter icosahedral particles. In this study, we aimed at
formulating HBc particles for the delivery of siRNA for gene
silencing in vitro and in vivo. We have previously reported
recombinant HBc particles expressing ZHER2 affibodies,
specifically targeting human epidermal growth receptor 2
(HER2)-expressing cancer cells (ZHER2-ΔHBc). siRNA was encapsulated within the ZHER2-ΔHBc particles following
disassembly and reassembly. The ZHER2-ΔHBc−siRNA hybrids were able to secure the encapsulated siRNA from serum and
nucleases in vitro. Enhanced siRNA uptake in HER2-expressing cancer cells treated with ZHER2-ΔHBc−siRNA hybrids was
observed compared to the nontargeted HBc−siRNA hybrids in a time- and dose-dependent manner. A successful in vitro polo-
like kinase 1 (PLK1) gene knockdown was demonstrated in cancer cells treated with ZHER2-ΔHBc−siPLK1 hybrids, to levels
comparable to commercial transfecting reagents. Interestingly, ZHER2-ΔHBc particles exhibit intrinsic capability of reducing the
solid tumor mass, independent of siPLK1 therapy, in an intraperitoneal tumor model following intraperitoneal injection.
KEYWORDS: virus-like particles, hepatitis B virus core particles, human epidermal growth factor receptor 2, affibody, gene silencing
1. INTRODUCTION
RNA interference (RNAi) is a biological mechanism whereby
small noncoding double-stranded RNAs (dsRNA) interfere
with the expression of a particular gene that shares
homologous sequence with dsRNA.1 Once small interference
RNA (siRNA), 20−30 nucleotide dsRNA, is present in the
cytoplasm of the cell, it is incorporated into a protein complex
known as RNA induced silencing complex (RISC). The whole
construct can induce a selective endonucleolytic cleavage of
the complementary target mRNA, which propagates gene
silencing.2−5 Gene silencing has been of great interest as a
powerful therapeutic strategy to regulate diseases of disordered
gene origin, including cancer.6,7 However, the therapeutic
applications of siRNA have been limited, due to its high
molecular weight and anionic charge, which causes difficulty
for siRNA to penetrate the cellular membranes by passive
diffusion mechanisms.8 In addition, siRNA activity is greatly
limited by rapid enzymatic degradation due to the presence of
ribonucleases (RNases) in serum.9
In order to achieve efficient cytoplasmic delivery of siRNA in
vitro and in vivo, delivery systems using nanoparticles have
been employed by researchers, including nonviral delivery
systems such as cationic liposomes, polymers, and carbon
nanotubes, and viral delivery systems such as viral-like particles
(VLPs).10−13 VLPs are hollow protein capsids derived from
viruses but lacking the viral genomes. They are ideal bio-
nanocarriers due to their biocompatibility, regulated structure,
and homogeneous size.14 Many medical applications, including
vaccine development and delivery of peptides and nucleic acids
have been approached using VLPs.15,16 Hepatitis B virus core
(HBc) particles are one of the VLPs that have been
investigated by researchers as nanocarriers for drug deliv-
ery.17−19 HBc particles are hollow nanoparticles (30−34 nm in
diameter), consisting of 180−240 copies of core monomers.20
Like other VLPs, HBc particles are noninfectious but still
inherit the essential features of the hepatitis B virus, including
the cell-penetrating ability. They also have the capability to
assemble and disassemble in a controlled manner allowing
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encapsulation of biomolecules including oligonucleotides.21,22
In addition, HBc particles can be genetically modified with
targeting molecules on the surface, which is beneficial for site-
specific delivery.23 These features make HBc particles suitable
candidates for delivery of therapeutics.
In this study, we aimed at formulating the HBc particles that
specifically target human epidermal growth receptor 2
(HER2)-expressing cancer cells, for the delivery of siRNA
and gene silencing in vitro and in vivo (Scheme 1). Polo-like
kinase (PLK1), a serine/threonine kinase that has key roles in
cell division and checkpoint regulation of mitosis, was chosen
as the targeting gene. PLK1 is known to overexpress in several
types of cancer and siRNA-mediated silencing of PLK1 in
cancer cells has been shown to result in reduced cell viability
with induction of apoptosis after depletion of PLK1
protein.24,25 We hypothesized that the HER2-targeting HBc
particles would be able to encapsulate and deliver the
functional siRNA (siPLK1) in vitro and induce gene silencing
in cancer cells in vitro causing cell death. We also hypothesized
that the encapsulation strategy is likely to improve the
longevity of siRNA in vivo following local administration.
HBc particles were prepared and characterized using E. coli
expression system. siRNA was encapsulated into HBc particles
using three different methods: disassembly and reassembly in
the presence of urea, osmotic shock, or disassembly and
reassembly by dithiothreitol (DTT)/CaCl2 treatment. siRNA
encapsulation efficiency was determined by gel retardation and
aldehyde sulfate latex beads assay. Cancer cells were treated
with HBc−siRNA hybrid particles, and the cell uptake was
assessed by flow cytometry. Cell cytotoxicity and gene
silencing of cancer cells treated with HBc−siPLK1 hybrid
particles were assessed using MTT assay and immunostaining
by Western blotting. In vivo silencing efficacy was assessed
using an intraperitoneal HER-2 expressing tumor model20
following intraperitoneal administration.
2. EXPERIMENTAL SECTION
2.1. Materials. Lithium chloride and ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) were obtained
from Amresco (USA). Ethylenediaminetetraacetic acid (EDTA)
disodium and dithiothreitol (DTT) were obtained from ForMedium
(UK). Calcium chloride (anhydrous) and urea (carbamide) were
obtained from Melford (UK). Ribonuclease A (from bovine
pancreas), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide), and dimethylsulfoxide (DMSO) were obtained from
Sigma-Aldrich (UK). Bovine serum albumin, lyophilized powder,
≥96% (agarose gel electrophoresis), was obtained from Sigma-Aldrich
(Germany). BD OptEIA Mouse TNF (Mono/Mono) ELISA kit was
obtained from BD Biosciences, USA. XenoLight D-luciferin potassium
salt was obtained from PerkinElmer (EU). GAPDH (14C10) rabbit
mAb, anti-rabbit IgG HRP-linked antibody, and anti-mouse IgG
HRP-linked antibody were obtained from Cell Signaling Technology
(UK). Anti-PLK1 antibody (35−206) was obtained from Abcam
(UK). Heat inactivated newborn calf serum (FBS) was obtained from
First Link Limited (UK). Lipofectamine2000, aldehyde/sulfate latex
(4% w/v, 4 μm), Alexa Fluor 488 NHS ester (succinimidyl ester),
MEM GlutaMAX Supplement, DMEM high glucose pyruvate,
advanced RPMI 1640 medium, PBS (10×) pH 7.4, trypsin-EDTA
(0.05%) phenol red, penicillin−streptomycin (10 000 U/mL), L-
glutamine (200 mM), GlutaMAX Supplement, SnakeSkin dialysis
tubing (10000 MWCO, 35 mm) and Pierce 16% formaldehyde (w/v,
methanol-free), Pierce BCA Protein Assay Kit were purchased from
Thermo-Fisher Scientific (UK). Noncoding siRNA (siNEG) (anti-
sense sequence, 5′-CAUCGUCGAUCGUAGCGCAA-3′), Atto-655-
labeled siNEG, and siPLK-1 (sequence 5′-CCUUGAUGAAGA-
AGAUCACdTdT-3′) were obtained from Eurogentec (Belgium).
Precision Protein StrepTactin-HRP conjugate was purchased from
Bio-Rad Laboratories, USA. Heparin (5000 IU/mL) (Sigma, UK) was
obtained from St. Thomas’s Hospital, UK. Plasmids pET-22b(+)-
dc149-His6 and pET-22b(+)-dc149-Z342-His6 were obtained from
Associate Professor Chiaki Ogino, Chemical and Science Engineering
Department, Kobe University, Japan.
2.2. Expression, Purification, and Assembly of HBc Particles.
Expression, purification, and assembly of ΔHBc and ZHER2-ΔHBc
particles were performed as previously published by Suffian et al.20
and detailed in SI. Protein concentrations of assembled ΔHBc and
ZHER2-ΔHBc particles were measured using NanoDrop ND-1000
UV−vis spectrophotometer (Thermo Fisher Scientific, USA).
2.3. siRNA Encapsulation in HBc Particles. Encapsulation of
siRNA into ZHER2-ΔHBc particles was performed using three methods
mentioned below. Fluorescently labeled nonfunctional siRNA,
siNEGAtto655 with emission at 650 nm, and ZHER2-ΔHBcAF480 with
emission at 525 nm were employed to assess encapsulation efficiency.
2.3.1. Method I: Disassembly/Reassembly Using Urea/NaCl.
Fluorescently labeled ZHER2-ΔHBcAF480 particles (30, 60, 120 (1:1
HBc/siNEG molar ratio), 240, 480 μg) were dialyzed against 1 L of
disassembly buffer containing 1.5 M urea, 0.5 M LiCl, 50 mM Tris,
and 5 mM dithiothreitol (DTT) at 4 °C overnight to disassemble
HBc particles into monomers. For siRNA encapsulation, siNEGAtto655
(0.25 μg) was mixed with ZHER2-ΔHBcAF480 in its disassembled form,
incubated for 1 h at 20 °C, and then dialyzed against 1 L of
reassembly buffer containing 50 mM Tris, 1 M NaCl overnight at 4
°C to reassemble the particles. Samples were concentrated to 100 μL
final volume using Vivaspin tubes (MWCO 10 kDa). To assess the
degree of complexation, samples were loaded onto 1% agarose gel ,
followed by gel electrophoresis at 100 V for 45 min for gel retardation
assay. Gel was then visualized under Alexa Fluor 647 and Alexa Fluor
488 channels using ChemiDocMP system (Bio-Rad Laboratories,
USA).
2.3.2. Method II: Osmotic Shock. Fluorescently labeled ZHER2-
ΔHBcAF480 particles (30, 60, 120, 240, and 480 μg) were mixed with
0.25 μg of siNEGAtto655 in 1× PBS and incubated for 10 min at 37 °C.
Osmotic shock was achieved by 5× dilution with distilled water.
Samples were incubated for 20 min at 37 °C then concentrated to 100
μL volume using Vivaspin tubes (MWCO 10 kDa). Samples were
loaded onto 1% agarose gel, underwent gel retardation assay, and were
then imaged using ChemiDocMP system as described previously.
2.3.3. Method III: Disassembly/Reassembly Using EGTA/CaCl2.
Fluorescently labeled ZHER2-ΔHBcAF480 particles (30, 60, 120, 240,
and 480 μg) were incubated with a disassembly buffer containing 50
mM Tris, 150 mM NaCl, 1 mM EGTA, and 20 mM dithiothreitol
(DTT) (pH 7.4) at 1:1 volume ratio for 1 h at 20 °C. For siRNA
encapsulation, siNEGAtto655 (0.25 μg) was mixed with the
disassembled HBc and incubated for 1 h at 20 °C. To reassemble
the particles, 0.1 M CaCl2 was slowly added to the mixture to reach a
final CaCl2 concentration of 10 mM. Samples were incubated for
another 1 h at 20 °C and kept overnight at 4 °C. Samples were
concentrated to 100 μL using Vivaspin tubes (MWCO 10 kDa).
Samples were loaded onto 1% agarose gel and underwent gel
Scheme 1. Description of the Proposed HBc-Based siRNA
Nanocarrier
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retardation assay then imaged using ChemiDocMP system as
described previously.
In all methods, samples were buffer-exchanged to 1× PBS prior to
addition to cells to maintain isotonicity.
2.4. Flow Cytometry Analysis of HBc−siNEG Hybrid
Particles. To confirm siNEGAtto655 encapsulation within ZHER2-
ΔHBcAF480 particles, flow cytometry analysis of HBc−siNEG particles
was performed. HBc particles were fluorescently labeled with Alexa
Fluor 488 as previously described.20 HBc−siNEG hybrid particles
were encapsulated at 1:1 HBc/siNEG molar ratio by the three
different encapsulation methods. Prepared HBc−siNEG hybrid
particles were reacted with aldehyde/sulfate latex (4% w/v, 4 μm)
microbeads (Invitrogen, USA) as previously described for other
proteins, with some modification.27 HBc−siNEG hybrid particles (40
μL) were incubated with 10 μL of aldehyde/sulfate latex (4% w/v, 4
μm) microbeads in a final volume of 500 μL for 15 min at room
temperature. Then, final concentration of 10 μM BSA from 100 μM
stock solution was added to each sample and incubated for another 15
min at room temperature. Then, an incubation in 1 mL of PBS was
conducted for another 75 min with gentle shaking; reaction was
stopped by incubation with 1 mL of 100 mM glycine made in PBS for
30 min at room temperature. HBc−siNEG-coated beads were then
washed twice in 1 mL of PBS containing 3% serum and resuspended
in 500 μL of 3% serum/PBS. HBc−siNEG-coated beads were
analyzed by flow cytometry using a BD FACS Calibur flow cytometer
(BD Biosciences, USA). A total of 100 000 events were gated, and
fluorescence was analyzed in triplicate by detecting Alexa Fluor 488
and Atto-655 fluorescence using FL-1 and FL-4 channel detector,
respectively, and BD CellQuest software (BD Biosciences, USA). The
median fluorescence intensity (MFI) of the beads is directly
proportional to siNEGAtto655 loaded in ZHER2-ΔHBcAF480.
2.5. In Vitro siRNA Stability in Serum. The degree of enzymatic
degradation induced by serum nucleases was studied by an incubation
of noncoding siRNA (siNEG) encapsulated within HBc particles with
fetal bovine serum (FBS). The HBc−siNEG hybrid particles at HBc/
siNEG molar ratio 1:1 (ratio at which complete siRNA encapsulation
was achieved) were prepared using method III (found to be the most
efficient encapsulation method) as described above. After complexes
were formed, FBS was then added to the complexes at a final
concentration of 50% v/v, and samples were incubated at 37 °C for 0,
24, or 48 h. After incubation, the reaction was stopped by adding
EDTA to a final concentration of 10 mM. Nonincubated and co-
incubated naked siNEG with FBS and EDTA were used as positive
and negative controls, respectively. Samples were subjected to a gel
retardation assay (2% agarose gel, 100 V, 30 min, GelRed 0.005% v/
v). Gel was then imaged under UV light using ChemiDocMP system
(Bio-Rad Laboratories, USA).
2.6. In Vitro siRNA Protection against RNase. The hybrid
particles at HBc/siNEG molar ratio 1:1 were prepared using method
III as described above. After forming the complexes, RNase A was
added to the complexes at a final concentration of 6.6 μg/mL.
Samples were then incubated at 37 °C for 0, 24, or 48 h. After
incubation, the reaction was stopped by adding EDTA to a final
concentration of 50 mM. Naked siNEG (0.25 μg) nonincubated and
co-incubated with FBS and EDTA were used as positive and negative
controls, respectively. Samples were subjected to a gel retardation
assay (2% agarose gel, 100 V 30 min, GelRed 0.005% v/v). Gel was
then imaged under UV light using ChemiDocMP system (Bio-Rad
Laboratories, USA).
2.7. Cell Culture. HER2-positive cells (HER2+), MDA-MB-435-
MLE and SKBR-3 cells, and HER2-negative (HER2−) MDA-MB-468
cells were selected in the present study. Their HER2 expression level
was confirmed previously.20 MDA-MB-435-MLE cells (human
melanoma in origin) were obtained by transfecting MDA-MB-435
cells (ATCC, HTB-129) with MUC1, luciferase, and ErbB2 genes as
previously reported.28 MDA-MB-435-MLE cells were cultured in
DMEM media; MDA-MB-468 human breast adenocarcinoma
(ATCC, HTB-132) and SKBR-3 human breast carcinoma (ATCC,
HTB-30) were cultured in advanced RPMI media. All culture media
were supplemented with 10% FBS, 50 U/mL penicillin, 50 μg/mL
streptomycin, and 1% L-glutamine at 37 °C in 5% CO2. All cells were
routinely grown in 75 cm2 canted-neck tissue culture flasks and
passaged twice a week using Trypsin/EDTA at 80% confluency.
2.8. In Vitro Cell Uptake Studies of HBc−siRNA Hybrid
Particles. siNEGAtto655 initial stock solution was prepared at 20 μM.
Prior to in vitro cell uptake, siRNA complex preparations were carried
out as follows: 1.0 μg (250 μL) of siNEGAtto655 in 5% dextrose was
mixed with an equal volume of Lipofectamine2000 (4.0 μg) in 5%
dextrose at 4:1 nitrogen (N)/ phosphate (P) charge ratio.
ΔHBcAF488− or ZHER2-ΔHBcAF488−siNEGAtto655 hybrid particles
were prepared using method III (found to be the most efficient
encapsulation method) at 1:1 HBc/siNEG molar ratio (containing
480 μg of HBc and 1.0 μg of siNEG), buffer-exchanged to 1× PBS, to
maintain isotonicity, and concentrated to 500 μL final volume using
Vivaspin MWCO 10 kDa. MDA-MB-468 (HER2−) and SKBR-3
(HER2+++) cells were seeded at a density of 1 × 105 cells/well in 24-
well plates and allowed to attach overnight. After washing with PBS
buffer, cells were then treated with naked siNEGAtto655, Lipofect-
amine−siNEGAtto655 complexes, or ΔHBcAF488−siNEGAtto655 or ZHER2-
ΔHBcAF488−siNEGAtto655 hybrid particles in serum-free media for 1, 4,
or 24 h. For 24 h treatment, after 4 h incubation with the hybrids, FBS
was added to each well to reach final FBS concentration of 10% v/v,
and incubated for another 20 h. At the end of incubation period, cells
were washed twice with PBS buffer, trypsinized, and centrifuged at 50
g for 5 min, and the cell pellet was resuspended in 250 μL of PBS
buffer. The internalization of HBc−siNEG hybrid particles Atto655 and
Lipofectamine-siNEGAtto655 treatments were used as a negative and
positive control, respectively. The data were analyzed using BD
CellQuest software (BD Biosciences, USA). The effects of the
presence of serum on the HBc−siRNA hybrid particle uptake were
examined by performing the same treatments described above in
complete serum-containing media for 1 or 24 h.
2.9. In Vitro Cytotoxicity Studies of HBc−siRNA Hybrid
Particles. MDA-MB-468 (HER2−) or SKBR-3 (HER2+) cells were
seeded at a density of 5 × 103 cells/well in 96-well plates and allowed
to attach overnight at 5% CO2 and 95% air at 37 °C. After washing
with PBS buffer, cells were treated with lipoplexes (siNEG or siPLK1
complexed with Lipofectamine2000 (4:1 N/P ratio)), ΔHBc−siNEG,
ΔHBc−siPLK1, ZHER2-ΔHBc−siNEG, or ZHER2-ΔHBc−siPLK1, all
at 1:1 HBc/siRNA molar ratio, containing increasing concentrations
of siRNA at 5, 10, or 20 nM in serum-free media for 4 h. After 4 h, the
formulation was discarded, cells were washed with PBS buffer,
complete medium was added, and cells were incubated for another 68
h. Cell viability was examined by MTT (3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. Briefly, the medium from
each well was removed after 72 h incubation and replaced with 120
μL of MTT solution (at a concentration of 5 mg/mL in PBS with a
further 1:6 dilutions in media prior to use). Cells were incubated for 3
h in 5% CO2 and 95% air at 37 °C. Solution was discarded, and
formazan was then solubilized in 200 μL of DMSO. The absorbance
was read at 570 nm (A570nm) using a FLUOstar OPTIMA plate reader
(BMG Labtech, Germany).
The effects of serum on the HBc−siRNA hybrid particle
cytotoxicity were examined by treating cells with the same complexes
and conditions mentioned above but in complete media instead. Cell
viability was examined by MTT assay as described previously.
2.10. In Vitro PLK1 Gene Silencing in HER2+ Cells. SKBR-3
and MDA-MB-435-MLE cells were seeded at a density of 5 × 105
cells/well in 6-well plates and allowed to attach overnight at 5% CO2
and 95% air at 37 °C. After washing with PBS buffer, cells were then
treated with lipoplexes (siNEG or siPLK1 complexed with Lipofect-
amine2000 (4:1 N/P ratio)) or ZHER2-ΔHBc−siNEG or ZHER2-
ΔHBc−siPLK1 at 1:1 HBc/siRNA molar ratio containing 20 nM
siRNA in serum-free media for 4 h, and then serum was added to the
treatment at a final concentration of 10% v/v, and cells were
incubated for another 20 or 44 h. After 24 or 48 h post-transfection,
cells were washed twice with ice-cold PBS buffer before lysis. Lysates
were examined by Western Blotting analysis to determine the level of
PLK1 expression (as described in section 2.15).
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2.11. Animal Studies and Tumor Inoculation. All animal
experiments were performed in compliance with the UK Home Office
(1989) Code of Practice for the housing and care of Animals used in
Scientific Procedures. MDA-MB-435-MLE cells (HER2+) were used
as the in vivo tumor model. Male NSG mice aged 4−6 weeks (Charles
River, UK) were injected intraperitoneally with MDA-MB-435-MLE
cells (5.0 × 106 cells in 100 μL PBS), and tumor progression was
observed by whole body bioluminescence imaging using IVIS Lumina
series III In Vivo Imaging Device (IVIS) (Caliper Life Sciences,
PerkinElmer, USA). In each imaging session, mice were administered
D-luciferin at 150 mg/kg subcutaneously. Animals were visualized at
12 min postluciferin injection to ensure consistent photon flux and
analyzed using Living Image software (Caliper Life Sciences,
PerkinElmer, USA). Photon flux from the tumor is proportional to
the number of live cells expressing luciferase.
2.12. Therapy Study. On day 4 post-tumor inoculation, NSG
mice were divided into 4 treatment groups (n = 7): PBS, ZHER2-
ΔHBc−siNEG, ΔHBc−siPLK1, and ZHER2-ΔHBc−siPLK1 treat-
ment. Doses used in therapy experiments were 4 μg of siNEG or
siPLK1 per injection per mouse; all treatments were injected
intraperitoneally. A total of seven doses of each treatment were
given at 3 day intervals on days 4, 7, 10, 13, 16, 19, and 22 post-tumor
inoculation. Tumor growth was observed by bioluminescence imaging
twice weekly (days 4, 7, 11, 14, 18, 21, and 25), as described above.
Mice were sacrificed on day 28. Only solid adherent tumor nodules
were excised and weighed, while tumor cells suspended in ascites were
discarded.
Figure 1. Encapsulation of siRNA with HBc particles at various HBc/siNEG molar ratios using three different methods. (A) Fluorescently labeled
nonfunctional siRNA (siNEGAtto655) (blue) was encapsulated with various amounts of fluorescently labeled ZHER2-ΔHBc (ZHER2-ΔHBcAF488)
particles (green), at HBc/siNEG molar ratio of 0 to 4, using three different methods, before performing the gel retardation assay. In method I,
siRNA encapsulation efficiency was increased with increasing molar ratios, with partial amount of free siRNA still being observed at molar ratio 4:1.
In methods II and III, siRNA encapsulation efficiency was increased with increasing molar ratios, with complete encapsulation observed at molar
ratio 4:1 and 1:1, respectively. (B) Aldehyde sulfate latex beads were coupled with 1:1 molar ratio HBc−siNEG hybrid particles, encapsulated using
one of the three encapsulation methods I−III. siNEGAtto655 encapsulation within ZHER2-ΔHBcAF488 particles by method III achieved highest
encapsulation efficiency, indicated by the fold increase of median fluorescence intensity (MFI) in FL4 channel. **p < 0.01, ***p < 0.001, relative to
untreated beads (one-way ANOVA test).
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2.13. Determination of TNF-α Concentration with ELISA.
Animals from the therapy study were sacrificed on day 28 (6 days
after the last injection), and sera was analyzed for mouse tumor
necrosis factor α (TNF-α). A separate group of tumor-bearing mice
was injected with lipopolysaccharide (LPS, 3 mg/kg) intraperito-
neally, and their sera were collected 1 h postinjection as positive
controls. Sera were diluted 1:2 using 1× PBS and analyzed using a BD
OptEIA Mouse TNF (Mono/Mono) ELISA set as per the
manufacturer’s protocol.
2.14. Organ Histology. Major organs (heart, lung, liver, spleen,
and kidney) and tumors were harvested and immediately fixed in 10%
neutral buffered formalin at 5 mm2 pieces. Tissue pieces were paraffin-
embedded and sectioned for hematoxylin and eosin (H&E) staining
according to the standard histological protocols at the Royal
Veterinary College, U.K. The stained sections were analyzed with a
Leica DM 1000 LED Microscope (Leica Microsystems, U.K.)
coupled with CDD digital camera (QImaging, U.K.).
2.15. Gene Silencing Evaluation by Western Blot. For in vitro
studies, cells were collected directly into a lysis buffer (50 mM Tris-
HCl, pH 8.0, 1.0% Triton X100, 150 mM NaCl, 5 mM EDTA) and
incubated on ice for 10 min. For in vivo studies, at sacrifice on day 28,
collected tumors were crushed directly into the lysis buffer and
incubated on ice for 30 min. Samples were then separated by
centrifugation at 20 800 g for 15 min at 4 °C. After the collection of
supernatant, total protein concentration was measured using BCA
protein assay kit. A total of 200 μg of protein was then taken from
each supernatant and separated on 15% SDS-PAGE gels for
electrotransfer onto a nitrocellulose membrane. After blocking in
3% skimmed milk for overnight, membranes were stripped for PLK1
(67 kDa) and GAPDH (40 kDa, a housekeeping gene (internal
reference)) detection separately. For PLK1, membranes were
immunoblotted with rabbit monoclonal PLK1 antibody at 1:1000
dilution as primary antibody, followed by HRP-linked anti-rabbit at
1:1000 dilution and Precision Protein StrepTactin-HRP conjugate at
1:10 000 dilution for secondary antibody. For GAPDH, membranes
were immunoblotted with mouse anti-GAPDH antibody at 1:1000
dilution (primary antibody), followed by mix of HRP-linked anti-
mouse at 1:1000 dilution (secondary antibody) and Precision Protein
StrepTactin-HRP conjugate at 1:10000 dilution. The specific bands
were identified using enhanced chemiluminescence (ECL) detection
system. The membrane was visualized using the ChemiDocMP (Bio-
Rad Laboratories, USA) and analyzed with Image Lab (Bio-Rad
Laboratories, USA) software. The quantity of PLK1 transcript was
normalized to GAPDH in each sample and correlated to the
normalized expression in naive cells to calculate the fold changes.
2.16. Statistics. In all experiments, data were presented as mean ±
SD, where n denotes the number of repeats. Significant differences
were determined using one-way ANOVA. The t-value, degrees of
freedom, and two-tailed significance (p-value) were resolved as *p <
0.05, **p < 0.01, and ***p < 0.001.
3. RESULTS
3.1. Disassembly/Reassembly of HBc Particles by
DTT/CaCl2 (Method III) Is the Most Efficient Method for
siRNA Encapsulation with Complete Complexation at
1:1 siRNA to Particle Molar Ratio. The encapsulation of
siRNA into HBc particles was first optimized. The recombi-
nant ZHER2-ΔHBc particles were expressed, purified, and
assembled. The assembled ZHER2-ΔHBc particles were then
fluorescently labeled with Alexa Fluor 488 succinimidyl esters
(ZHER2-ΔHBcAF480) as described previously.20 Fluorescently
labeled noncoding siRNA (siNEGAtt0655) was encapsulated into
ZHER2-ΔHBcAF480 particles using three different methods,
disassembly/reassembly by urea (method I), osmotic shock
(method II), or disassembly/reassembly by DTT/CaCl2
(method III), to form HBc−siRNA hybrid particles; all
methods are schematically described as shown in Figure S1.
In method I, urea was used as a denaturing agent to weaken
the protein−protein interactions between HBc monomers,
thus loosening the particle formation, which is expected to
allow the siRNA to penetrate into the HBc particles.29,30
Additionally, the high salt concentration of NaCl added in the
assembly stage is expected to increase the electrostatic
repulsion between the protein monomers, promoting the
ZHER2-ΔHBcAF480 assembly in an organized manner forming of
HBc−siRNA hybrid particles.31 In method II, an osmotic
shock was induced to encapsulate siRNA following reported
protocols32 with some modifications. An osmotic shock or
osmotic stress introduced by a sudden change in the solute
concentration around the particles is expected to cause the
particles’ pores to swell up, allowing the entry of the siRNA
into the particles.33 This method is not expected to cause
disassembly of the particles. In method III, HBc particles were
disassembled in the presence of a chelating agent, EGTA, and a
reducing agent, DTT.34 An EGTA−DTT combination is
therefore expected to completely disrupt the HBc particles;
EGTA has high affinity for Ca2+. As the assembly of HBc
particles is highly Ca2+-dependent, HBc was then reassembled
by adding Ca2+ to increase the electrostatic repulsions between
the protein monomers.35,36 The size of empty HBc particles
was confirmed to be ∼30 nm.20
Figure 2. Stability studies of HBc−siNEG hybrid particles against serum and RNase. Gel retardation assay for HBc−siNEG hybrid particles
subjected to (A) serum; (B) RNase at HBc/siNEG 1:1 molar ratio. The hybrid particles were prepared at a fixed siNEG amount of 0.25 μg. HBc−
siNEG hybrid particles were incubated with 50% v/v FBS (0, 24, or 48 h) or RNase (0, 24, or 48 h) at 37 °C. EDTA was used to inactivate serum
proteins.
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The siRNA encapsulation profiles using the three different
methods were assessed and compared using gel retardation
assay as shown in Figure 1A. The green color is assigned to
HBc while blue color indicates either free or complexed
siRNA. Decreasing signals of free siRNA bands (blue color)
observed at the bottom of the gel is a sign of complexation. In
method I, siRNA encapsulation efficiency was improved with
increasing complexation molar ratios of HBc/siRNA from 2:1
to 4:1. Some free siRNA was still observed even at 4:1 HBc/
siRNA molar ratio. In methods II and III, complete
encapsulation was achieved at HBc/siRNA molar ratio 4:1
and 1:1, respectively. No free siRNA was detected at the
bottom of the gel in such conditions with the concomitant
observation of increased fluorescence in the wells.
Another technique, the bead coupling assay, schematically
presented in Figure S2, was employed to confirm siRNA
incorporation into ZHER2-ΔHBc particles by flow cytometry
using FL-1 (Z-ΔHBcAF488) and FL-4 (siNEGAtto655) channels.
Using this method, siRNA encapsulated using method III
showed the highest amount of siRNA encapsulation, compared
to method I and method II (Figure 1B). This result is in
agreement with the results obtained by gel retardation assay. It
was concluded that approximately 1 mol of siRNA can be
encapsulated in 1 mol of HBc particles using method III.
Method III was used in the subsequent studies.
3.2. HBc−siRNA Hybrids Are Stable against RNase
and in Serum. The ability of HBc−siRNA hybrids to protect
siNEG from degradation by nuclease was evaluated by
challenging the hybrid particles against serum. Naked siNEG
and HBc−siNEG hybrid particles were incubated at 37 °C in
50% v/v FBS for 0, 24, or 48 h. As shown in Figure 2A, FBS
alone exhibited weak signals shown in the middle of the gel
Figure 3. In vitro uptake studies using HBc−siNEG particles in HER2− (MDA-MB-468) and HER2+++ (SKBR-3) expressing cancer cells. Fold
increase in median fluorescence intensity (MFI), relative to naive cells, following 1, 4, or 24 h treatment with siNEGAtto655 (negative control),
Lipofectamine2000 complexed with siNEGAtto655 (positive control), and ΔHBcAF488 or ZHER2-ΔHBcAF488 particles complexed with siNEGAtto655.
Cellular uptake was assessed using flow cytometry (FL-1, FL-4). A significantly higher siNEGAtto655 uptake was observed for ZHER2-ΔHBc−siNEG
particles compared to ΔHBc−siNEG particles, in a time-dependent manner (FL-1, FL-4). Values are expressed as fold increase in MFI ± SD (n =
6). **p < 0.01, ***p < 0.001, relative to MDA-MB-468 cells (one-way ANOVA test).
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(first lane) that are located differently from the signals of either
free or encapsulated siNEG occurring at the bottom of the gel
or at the wells, respectively, shown in other lanes. After 24 h
incubation with serum, naked siNEG was almost degraded,
with complete degradation of siNEG observed at 48 h
incubation.
In contrast, HBc−siNEG particles exhibited strong signals
for encapsulated siNEG in the well at all time points.
Interestingly, free siNEG signals were also present at the
bottom of the gel, even at the 0 h time point, suggesting a
partial release of siNEG from the hybrids in the presence of
serum. These results suggest that complexation with HBc
particles improves siRNA stability in the presence of serum.
The ability of HBc−siRNA hybrids to protect siRNA against a
ribonuclease (RNase) was evaluated by incubating the hybrids
with RNase for 0, 24, or 48 h at 37 °C. As shown in Figure 2B,
naked siRNA was completely degraded after 24 h incubation
with RNase. In contrast, strong signals were observed in the
wells of HBc−siNEG particles even after 48 h of incubation
with the RNase, indicating that the HBc particles can protect
siNEG from enzymatic degradation.
3.3. HER2-Targeting HBc−siRNA Hybrids Are Selec-
tively Taken Up in HER2-Positive Cancer Cells in Vitro.
The intracellular uptake of HBc−siRNA hybrids in MDA-MB-
468 (HER2−) and SKBR-3 (HER2+) cells was evaluated by
flow cytometry via FL-1 (ZHER2-ΔHBcAF488) and FL-4
(siNEGAtto655) channels and expressed as fold increase in
median fluorescent intensity (MFI) (Figure 3). All cells were
treated with naked siNEGAtto655, Lipofectamine−siNEGAtto655
complexes, ΔHBcAF488−siNEGAtto655 or ZHER2-ΔHBcAF488−
siNEGAtto655 hybrids for 1, 4, or 24 h. As shown in Figure 3,
treatment of SKBR-3 cells with ZHER2-ΔHBcAF488−siNE-
GAtto655 promoted an apparent fold increase at both FL-1
and FL-4 channels in a time-dependent manner (last green
bars) in contrast to lower uptake measured for treatments of
ΔHBcAF488−siNEGAtto655 hybrids in both cells. The trend of
signals of taken up siNEGAtto655 (FL-1), matched that of
ΔHBcAF488 and ZHER2-ΔHBcAF488 from complexes (FL-4).
Taken together, these results indicate that HBc−siRNA hybrid
particles were able to deliver siRNA into the cells in vitro, with
ZHER2-ΔHBcAF488−siNEGAtto655 hybrids exhibiting a signifi-
cantly higher uptake profile than ΔHBcAF488−siNEGAtto655
Figure 4. Cell viability of cancer cell lines treated with siRNA−HBc particles in vitro. (A) MDA-MB-468 and SKBR-3 cell lines were treated with
siNEG and siPLK1 at increasing concentration (5, 10, and 20 nM) in serum free media for 4 h followed by incubation in complete media for
another 68 h. Treatment groups include 5% dextrose, 1×PBS, lipoplexes (siNEG or siPLK1 in complex with Lipofectamine2000 (4:1 N/P)),
ΔHBc−siNEG, ΔHBc−siPLK1, ZHER2-ΔHBc−siNEG, or ZHER2-ΔHBc−siPLK1, all at 1:1 HBc/siRNA molar ratio. Cell viability was analyzed and
expressed as a percentage of naive cells, determined by MTT assay. (B) Percentage cell viability (SKBR-3 cells) after 72 h transfection ±10% serum
at 20 nM final concentration. Cell viability was analyzed and expressed as a percentage of naive cells, determined by MTT assay. Values are
expressed as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, relative to naive (one-way ANOVA test).
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hybrids in HER2+ SKBR-3 cells. The intracellular uptake of
HBc−siRNA hybrid particles in vitro was also studied in the
presence of serum. Results suggested that the presence of
serum slightly but significantly reduced the uptake of the
hybrids overall (FL-1, FL-4) in both cell types (Figure S3).
3.4. HER2-Targeting HBc−siPLK1 Hybrids Are Func-
tionally Active in Vitro in the Presence or Absence of
Serum. The cytotoxic effect of HBc−siRNA hybrids was
assessed in MDA-MB-468 (HER2−) and SKBR-3 (HER2+)
cells in vitro. Nonfunctional siNEG was replaced with
functional siRNA specific to PLK1 gene (siPLK1), in order
to assess the gene-silencing efficacy. Cells were treated with 5,
10, or 20 nM siNEG or siPLK1 encapsulated in nontargeted
ΔHBc or targeted ZHER2-ΔHBc particles for 72 h, and cell
viability was determined by MTT assay. Lipofectamine2000−
siPLK1 complexes were used as a positive control (Figure 4A).
As expected, cells treated with ΔHBc−siPLK1 showed no
significant toxicity in both cell lines. These results are in
agreement with those obtained for intracellular uptake studies
for ΔHBc particles alone as these particles lose their non-
specific binding due to lack of the arginine-rich domain.20 A
significant dose-dependent reduction in cell viability was
observed for Lipofectamine2000−siPLK1 in both cell lines.
Treatments with ΔHBc−siPLK1 did not cause significant
cytotoxicity in both cell lines. In contrast, treatments with
ZHER2-ΔHBc−siPLK1 induced 30−40% cell death in SKBR-3
cells but not MDA-MB-468 cells. Interestingly, when SKBR-3
cells were treated with ZHER2-ΔHBc−siNEG, a significant
amount, approximately 10%, cell death was observed. This
could be due to some intrinsic toxicity exhibited by ZHER2-
ΔHBc, due to the presence of the affibody, that is, HER2
receptor blockade activity, since such toxicity was not observed
when ΔHBc hybrids were tested under same conditions.
The cytotoxic effect of HBc−siRNA hybrids in HER2+ cells
was further studied with subjection to serum competition. Cell
viability of SKBR-3 cells treated with 20 nM of siNEG or
siPLK1 encapsulated in ZHER2-ΔHBc particles was assessed by
MTT assay at 72 h postincubation. Lipofectamine2000−
siPLK1 complexes were used as a positive control (Figure 4B).
Similar reduction in cell viability was seen for cells treated with
Lipofectamine2000-siPLK1 regardless of the presence of
serum. A slight reduction in cytotoxicity was observed for
ZHER2-ΔHBc−siPLK1 in the presence of serum (***p <
0.001), but this was significantly lower than equivalent siNEG
group.
3.5. Efficient PLK1 Knock-down Is Confirmed in Vitro
by Western Blotting. To confirm if the reduction in cell
viability in the case of ZHER2-ΔHBc−siPLK1 hybrid treatment
was associated with PLK1 gene silencing, the levels of PLK1
protein expression in vitro were examined using Western
blotting. HER2+ cells, SKBR-3 and MDA-MB-435-MLE cells,
were incubated with ZHER2-ΔHBc−siPLK1 hybrids for 24 or
48 h. GAPDH, a housekeeping gene, was used as an internal
control. Lipofectamine2000−siPLK1 complexes were included
Figure 5. PLK1 gene silencing in HER2+++ cancer cells by Western blotting. (A, C) Western blots and (B, D) quantitative analysis of PLK1
expression in (A, B) SKBR-3 and (C, D) MDA-MB-435-MLE cell lines. Treatment groups including lipoplexes (siNEG or siPLK1 in complex with
Lipofectamine2000 (4:1 N/P)) and ZHER2-ΔHBc−siNEG and ZHER2-ΔHBc−siPLK1 at 1:1 HBc/siRNA molar ratio and 20 nM siRNA
concentration. GAPDH gene was used as a housekeeping gene (internal control). An efficient siPLK1 knock-down was achieved with lipoplexes
and ZHER2-ΔHBc−siPLK1 hybrids. ***p < 0.001, relative to groups of siNEG (one-way ANOVA test).
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as a control transfecting agent. There was a clear difference in
gene silencing efficacy between the two vectors in SKBR-3
cells, where ZHER2-ΔHBc−siPLK1 hybrids showed more
efficient PLK1 gene knockdown than Lipofectamine2000−
siPLK1 complexes as measured by PLK1 protein level (Figure
5A,B). In the case of ZHER2-ΔHBc−siPLK1 hybrids trans-
fection, PLK1 expression was reduced to 33.4% ± 1.5% and
20.4% ± 0.6% at 24 and 48 h post incubation, respectively,
compared to naive cells. In the case of Lipofectamine2000−
siPLK1 complexes, the protein levels were 53.6% ± 0.5% and
33.0% ± 1.0% after the same incubation times (***p < 0.001)
(Figure 5B).
In comparison, incubation with Lipofectamine2000−siPLK1
complexes resulted in a better PLK1 gene knockdown than
ZHER2-ΔHBc−siPLK1 hybrids after 24 h in MDA-MB-435-
MLE cells (45.4% ± 2.2% vs 66.9% ± 1.3%, Figure 5C,D;
***p < 0.001). However, ZHER2-ΔHBc−siPLK1 hybrids
showed better PLK1 gene knockdown after 48 h, where
protein expression was reduced to 23.4% ± 0.5%, compared to
only 26.7% ± 0.6% in the case of Lipofectamine2000−siPLK1
transfection (*p < 0.01) (Figure 5D). The results overall
indicated that more potent in vitro gene silencing could be
achieved using the ZHER2-ΔHBc−siPLK1 hybrids than Lip-
ofectamine2000−siPLK1 in cell models tested.
3.6. ZHER2-ΔHBc and Not siPLK1 Treatment Results in
Reduction in Intraperitoneal Solid Tumor Mass in Mice.
Representative in vivo bioluminescent images for all treatments
on day 21 post-tumor inoculation is shown in Figure 6A.
Quantitative analysis of bioluminescence signals from mice
whole body is illustrated in Figure 6B. No significant
differences in bioluminescence signals were observed between
PBS and ΔHBc−siPLK1 treatments. Unexpectedly, signifi-
cantly higher signals were obtained on day 25 in groups
receiving ZHER2-ΔHBc−siNEG (**p < 0.01) and ZHER2-
Figure 6. Assessment of tumor bioluminescence and solid weight tumors in HER2-expressing intraperitoneal tumor mouse models. NSG mice (n =
7) were intraperitoneally injected with 5.0 × 106 MDA-MB-435-MLE cells. Mice were treated with PBS, ZHER2-ΔHBc−siNEG (4 μg of siNEG per
injection per mouse), ΔHBc−siPLK1 (4 μg of siPLK1 per injection per mouse) and ZHER2-ΔHBc−siPLK1 (4 μg of siPLK1 per mouse),
intraperitoneally. Seven treatments were given intraperitoneally at 3 day intervals, commencing on day 4 post-tumor inoculation. Tumor growth
was observed by whole body imaging. (A) Representative images for in vivo bioluminescent imaging are shown. (B) Growth curves of MDA-MB-
435-MLE tumors. (C) Weight of tumors excised from mice after sacrifice. Data expressed as mean ± SD (n = 7). *p < 0.05, **p < 0.01, ***p <
0.001, relative to group of PBS (one-way ANOVA test).
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ΔHBc−siPLK1 (***p < 0.001). No significant difference
between these two treatments was observed. Bioluminescence
signals are expected to be directly proportional to the tumor
metabolic activity. It is however worth mentioning that the
signals here are obtained from both semiadherent in ascites
and adherent cells forming tumor nodules in the peritoneal
cavity, due to the nature of this tumor type. The metabolic
activity of singly suspended cells is likely to be higher than
those obtained from tumor nodules because the latter are likely
to develop a necrotic core. To measure the solid tumor load,
the weight of total tumors modules collected post-mortem was
measured. Interestingly, contrary to the trends obtained from
bioluminescence imaging, weights of solid tumors treated with
ZHER2-ΔHBc−siNEG (0.72 ± 0.26 g, *p < 0.05) and ZHER2-
ΔHBc−siPLK1 (0.72 ± 0.14 g, **p < 0.01) were significantly
lower than those of the PBS group (1.01 ± 0.14 g) (Figure
6C). The level of PLK1 protein expression in HER2-expressing
tumors was examined from the protein lysate of MDA-MB-
435-MLE tumors. PLK1 proteins were extracted from the solid
tumor nodules, collected on day 28 at sacrifice, and the PLK1
expression was evaluated by Western blotting (Supporting
Information Figure S4A). ΔHBc−siPLK1 and ZHER2-ΔHBc−
siNEG were included to account for any nonspecific toxicity of
the siRNA or the ZHER2-ΔHBc particles, respectively. The
PLK1 expression level of PBS group was normalized to 100%
± 1.49% relative to expression of GAPDH. Intraperitoneal
treatment of ZHER2-ΔHBc−siPLK1 hybrid particles showed
slight but significant reduction in the PLK1 protein levels
Figure 7. Microscopic examination of major organs and tumor sections of MDA-MB-435-MLE tumor-bearing NSG mice. Mice were treated with
PBS, ZHER2-ΔHBc−siNEG (4 μg of siNEG/mouse), ΔHBc−siPLK1 (4 μg of siPLK1/mouse), and ZHER2-ΔHBc−siPLK1 (4 μg of siPLK1/
mouse), intraperitoneally. Seven treatments were given intraperitoneally at 3 day intervals, commencing on day 4 post-tumor inoculation. At day
28, the mice were sacrificed, and the organs were immediately fixed in 10% neutral buffer formalin as 5 mm3 pieces. These pieces were then
paraffin-embedded for hematoxylin and eosin stains (H&E) and analyzed by microscopy. No signs of toxicity were observed in heart, lungs, liver,
spleen, and kidneys. Red arrows point to the necrotic area in tumor section (pinkish area). Scale bars are 50 μm.
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(∼89.74% ± 2.23%, **p < 0.01) (Supporting Information
Figure S4B). Although these values appear lower than PBS
group, the gene silencing effect might not be enough to infer
with tumor growth in vivo.
3.7. In Vivo Biocompatibility. No significant difference in
whole-body weight was observed between the PBS group and
the other treatment groups (Supporting Information, Figure
S5). The levels of the pro-inflammatory cytokine TNF-α were
determined to assess the possibility of inflammation-mediated
toxicity after intraperitoneal administration of HBc particles.37
TNF-α levels were measured in serum samples collected from
MDA-MB-435-MLE tumor-bearing NSG mice after therapy.
Sera from mice injected with LPS (3 mg/kg) intraperitoneally
were taken at 1 h postinjection and used as a positive control.
Significantly high levels of TNF-α (1048 ± 320 pg/mL, ***p
< 0.001) were observed in the serum from mice treated with
LPS (Supporting Information, Figure S6). On the other hand,
no significant differences in serum TNF-α levels were found in
mice receiving 7 doses of ZHER2-ΔHBc−siNEG, ΔHBc−
siPLK1, or ZHER2-ΔHBc−siPLK1 (12−21 pg/mL) intra-
peritoneally within 28 days compared to the PBS group (13
± 7 pg/mL).
Histological examination of the major organs (heart, lung,
liver, spleen, and kidney) with H&E staining exhibited no
obvious histological changes compared to control animals
(Figure 7). In mice treated with ZHER2-ΔHBc−siPLK1, tumors
showed regions of necrosis (Figure 7, Supporting Information,
Figure S7, red arrows), which was not observed in tumors from
control and ZHER2-ΔHBc−siNEG treated mice. Both early
stage (fragmented and small nucleus) and late stage (ghost
shells without nucleus) necrosis were found in necrotic areas,
indicating an accumulative therapeutic effect of ZHER2-ΔHBc−
siPLK1 throughout the therapy time course.
4. DISCUSSION
In this study, we validated the utilization of recombinant
HER2-targeting HBc particles as an efficient delivery carrier for
siRNA. To the best of our knowledge, studies on delivering
siRNA using HBc particles simultaneously with a specific
HER2 targeting to cancer cells have not yet been reported.
However, many studies have used HBc particles to deliver
small molecules including oligonucleotides38 and drugs39 to
cancer cells. Lee et al. reported the use of the HBc particles
encapsulated with a green fluorescent protein by dissociating
the HBc particles in the presence of urea and subsequently
reassembling by dialysis to remove the denaturant.39 In
another study, Beterams et al. successfully packaged up to
240 subunits of 17 kDa nuclease into the interior of
recombinant HBc particles. Interestingly, the packaged
nuclease was enzymatically active and the structure of the
particles was not affected.40
HBc particles like other virus-like particles have the capacity
to load RNA. Encapsulating and loading nucleic acids within
HBc particles is simpler than any other small molecules. This is
due to the properties of nucleic acids, which are usually bigger,
and the protein capsids have emerged to carry and encapsulate
a similar type of cargo, in this case, their own viral genomes. In
addition, dissimilar to the lipid-based, metal-based, and
polymer-based nanocarriers, HBc particles are highly uniform,
can be reproduced with an actual number of monomer
proteins, and can be organized in a consistent arrangement.
HBc particles are expected to possess a significantly reduced
lot-to-lot variability and exact cargo release properties.
Furthermore, once the HBc particles managed to internalize
in the targeted cells, they are able to disassemble and unleash
all of the therapeutic molecules at once, compared with
polymeric nanoparticles, which degrade and slowly release the
loaded molecules over time. Even though slow cargo release
might occasionally be propitious, in many cases, especially in
cancer treatment, an immediate cargo release is preferred. HBc
particles also have the capability to be functionalized
chemically or genetically to exhibit fragments like antibody
or peptide, for specific cellular targeting.41 Such characteristics
make them distinguishable from other types of nanocarriers for
nucleic acid delivery. These make HBc particles have more
advantages than other nanoparticles. Taking advantage of the
ability of HBc particles to encapsulate small biomolecules into
their interior, we aimed at formulating recombinant HBc
particles for delivery of siRNA capable of binding and possibly
blocking HER2 receptors, allowing a combinatory approach to
kill HER+ cancer cells.
We demonstrated that siRNA encapsulation using method
III showed the highest amount of siRNA encapsulated into
HBc particles at the 1:1 HBc/siRNA molar ratio, compared to
method I and method II. Method I was not able to encapsulate
a higher amount of siRNA compared to method III even
though urea is a known denaturing agent for its compatibility
with protein folding. This could be due to the incomplete
reassembly caused by NaCl. The ionic strength from the
monovalent sodium ions might be able to trigger the HBc
protein assembly,42 but not in an amount sufficient to increase
the electrostatic charges between HBc protein monomers to
cause complete reassembly of the proteins. Our result showed
an enhancement of siRNA encapsulation using the osmotic
shock in method II compared to method I. However, complete
siRNA encapsulation was only achieved at 4:1 HBc/siRNA
molar ratio. Studies reported that encapsulation of nucleic
acids using osmotic shock is pH-dependent. Braun et al.
reported that the loading of oligonucleotide and plasmid DNA
into polyoma VP1 virus-like particles achieved the highest
encapsulation efficiency only at acidic pH of 5.38 In our study,
pH 7.4 was maintained throughout the experiment, which
could be the reason for the lower siRNA encapsulation than
expected. Nevertheless, we successfully encapsulated siRNA
into HBc particles using method III, a new combination
method involving the use of EGTA and DTT. EGTA and
DTT were required for the particle disassembly as EGTA has
high affinity to Ca2+. HBc particle assembly is highly Ca2+-
dependent,35,36 and DTT has the ability to break the disulfide
bringing between HBc dimers.35
The blue intensity reflects quantitatively the amount of free
migrating siRNA. Blue signals in the well are only semi-
quantitative (larger aggregates may float out of the wells during
electrophoresis) and are representative of siRNA in the
complexed form. In method I, it was not surprising to see a
reduction in the amount of free migrating siRNA as the
amount of HBc increased indicating an increased degree of
siRNA complexation. In case of methods II and III, the
complexation was efficient and occurred at all ratios used so
that no free siRNA could be seen at all the tested ratios.
Instability poses a major problem in siRNA applications due
to its degradation by the activity of serum or enzymes. We
tested the stability of HBc−siRNA hybrid particles by
challenging the hybrid particles with serum or RNase. Agarose
gel results indicated that the HBc−siNEG hybrid particles
confer great siRNA protection ability under several test
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conditions. In this study, HBc particles were expected to be
able to protect siNEG from enzymatic degradation, but
substantial signals can be seen at 0 h either due to partial
instability or the presence of some surface-absorbed siRNA,
which may have been detached in the presence of serum. The
results explained the reduced uptake of siRNA in the presence
of serum (Figure S3).
siRNA is an anionic macromolecule that is unable to enter
cells by passive diffusion mechanisms, and thus an appropriate
delivery system is needed to enhance its cellular uptake
efficiency. Many studies have reported successful siRNA
delivery in vitro using nanoparticles. For example, Lipofect-
amine2000, a cationic lipid formulation, is widely used for in
vitro siRNA transfection, which succeeded in transfecting
siRNA in a mouse’s vascular endothelial cells.43 Recently,
Pereira et al. reported the use of carbon nanotube−liposome
hybrids to deliver siRNA in human epithelial lung carcinoma
A549 cells.44 In our study, a successful delivery of siRNA in
vitro was achieved using ZHER2-ΔHBcAF488−siNEGAtto655
hybrids in two different HER2-expressing cancer cell lines.
SKBR-3 cells, overexpressing HER2 receptors on cell
membrane surface, showed an enhanced uptake of ZHER2-
ΔHBcAF488−siNEGAtto655 hybrids compared to ΔHBcAF488−
siNEGAtto655 hybrids. This could be attributed to the presence
of ZHER2 affibody expressed on the particle surface that
specifically binds the HER2 receptor.26,45 In competition
experiments using serum, intracellular uptake of HBc−siRNA
hybrids was still taking place but with a slight reduction, which
was also observed with the positive control, Lipofect-
amine2000−siNEGAtto655 complexes. The enhanced cellular
uptake of the ZHER2-ΔHBcAF488−siNEGAtto655 hybrids revealed
ZHER2-ΔHBc as a promising system for the delivery of genetic
material. Comparison and quantification of uptake was done
by flow cytometry. Confocal laser scanning microscopy, to
confirm site of localization inside the cells, could not be
performed on MDA-MB-435 cells due to the semiadherent
nature of the cells.
In the cytotoxicity assessments, a significant 10% cell death
was observed for ZHER2-ΔHBc−siNEG hybrids, whereas
ΔHBc−siNEG hybrids did not show any significant cytotox-
icity. When the nonfunctional siNEG was substituted with a
siRNA sequence specific for PLK1 gene, a further significant
reduction in cell viability was achieved. The consequent
quantitatively assessments by Western blotting of PLK1
protein expression confirmed the PLK1 knockdown after
ZHER2-ΔHBc−siPLK1 hybrid treatments using the two HER2
positive cell lines, SKBR-3 or MDA-MB-MB435-MLE. The
gene-silencing efficacy was even more efficient compared to
Lipofectamine2000 transfection, which is encouraging for
further in vivo investigation.
The choice of the location of the tumor model and route of
administration was based on our previous study where tumor
uptake of ∼10% of the total injected HBc dose per gram of
tissue was achieved.20 Furthermore, even though the
orthotopic inoculation of cancer cells in the mammary fat
pad contributes a better model to resemble the early stages of
breast cancer advancement, the IP tumor mouse model
provides a much more precise representation of clinical disease
progression of tumors, which includes metastatic dissem-
ination. While combination of HER2-targeted HBc particles
and siPLK1 (or siNEG equivalent formulation) resulted in
apparent increase in cancer cell population based on whole
body bioluminescence imaging, tumor weight measurement of
solid tumor nodules showed contradicting results where ZHER2-
ΔHBc-based treatments (siNEG or siPLK1) displayed
significant reduction in tumor weights. This discrepancy in
findings using both techniques was unexpected. A possible
explanation could be the fact that the cell line used in this
study is a semiadherent cell line.28 Due to this property, tumor
cells can be present in ascites fluid, also known as malignant
ascites, or as adherent tumor nodules in vivo.46 It is expected
that the bioluminescence signals measured are the sum of
suspended cells and larger adherent tumor nodules. The
discrepancy seen between the bioluminescence and tumor
weight measurements may be due to the shift in tumor status
from adherent nodules (low bioluminescence) to suspension
form (higher bioluminescence). This seems to be primarily a
function of the ZHER2:342 affibody and not the siPLK1
treatment. Further studies are needed to understand how
ZHER2:342 affibody−receptor binding may influence cell to cell
communication and adhesion.
Immune response is always the main concern when it comes
to gene therapy. Most of the toxicity associated with VLP
nanocarriers arises from the innate and adaptive immune
response to their capsids. Systemic administration of VLPs will
cause the release of pro-inflammatory cytokines and chemo-
kines, including TNF-α.47,48 Here, to abolish the immune
response that might be induced from our HBc particles, we
modified the major immunodominant region located between
amino acids 75 and 83 with our ZHER2 affibody. This particular
sequence has the capacity to exhibit a strong immune
response.49,50 An establishment of targeting moieties at this
sequence should be able to abolish a strong immune response
by the host.51−53 The ELISA assay results showed no
significant TNF-α level was observed in mice treated with
recombinant HBc particles.
Western blotting data hinted that PLK1 silencing worked
very slightly (∼10%), but this is obviously not sufficient or
therapeutically acceptable. It is acknowledged that the siRNA
dose injected into mice was low compared what has been used
in other studies. The siPLK1 dose was relatively low (0.2 mg of
siRNA/kg per injection) compared to what have been reported
in other studies with systemic siPLK1 administration.54,55 The
limited dose was due to the low siRNA encapsulation efficiency
obtained with the studied particles. Future work should focus
on methods to improve siRNA loading so that higher siRNA
doses, at lower nanocarrier dose, can be achieved. Taking
together the results of therapy (weight measurements on solid
tumor nodules) and Western blotting studies, one may think
that both the intrinsic bioactivity of ZHER2-ΔHBc and siPLK1
silencing took place. The overall potency however is minimal
and needs further improvement. The histology analysis
suggested that the administration of HER2-targeted HBc
particles might induce apoptosis or necrosis to the solid tumors
itself.
Another possible factor of the low efficacy might be due to
challenges encountered with intraperitoneal delivery route of
nucleic acids. It has been reported that local intraperitoneal
delivery results in rapid clearance of the nanocarriers from the
peritoneal cavity. This rapid clearing from the cavity to the
systemic circulation most probably will limit the amount of
nanocarriers that reach the actual target cells or tissues.56 In
addition, IP fluid possesses a complex biological environment,
so stability of our hybrids should also assessed under
conditions mimicking those of intraperitoneal fluid for a better
representation of in vitro to in vivo correlation.57
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5. CONCLUSION
We developed a new siRNA delivery carrier composed of
recombinant HBc particles and ZHER2 affibody. ZHER2 affibody
on the particle surface allowed the recombinant HBc particles
to be recognized by the HER2 receptors overexpressed on the
cancer cell surface and be subsequently internalized.
Furthermore, gene silencing studies with siPLK1 revealed
that HBc particles were able to adequately silence PLK1 genes
to commensurate levels to cationic lipid nanocarriers in vitro.
Following intraperitoneal administration in intraperitoneal
xenografts, combination of HER2-targeted HBc particles and
siPLK1 did not produce any delay of tumor growth in vivo;
however, targeted HBc particles induced a reduction in the
weight of solid tumors. Mice after treatments did not show
elevated TNF-α levels in serum, and no obvious histological
changes in major organs were observed post-mortem
indicating that our HBc particles are biocompatible in vivo.
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